Eplerenone PCD Pharma Franchise Company
Cafoli Lifecare offers an Eplerenone PCD pharma franchise built on 3 tablet formulations manufactured at WHO-GMP certified facilities. This gives franchise partners a modern cardiology and hypertension line prescribed by cardiologists and physicians.
What is Eplerenone?
Eplerenone is a selective aldosterone-receptor antagonist (mineralocorticoid receptor blocker). By blocking aldosterone it reduces sodium and water retention and blood pressure, and it improves outcomes in heart failure — with far less gynaecomastia than spironolactone because of its receptor selectivity. Read its profile on MedlinePlus.
Therapeutic Applications
Eplerenone is prescribed for hypertension and for heart failure following myocardial infarction and in chronic systolic heart failure to reduce cardiovascular mortality. It is also used in resistant hypertension and primary aldosteronism. Prescriptions come mainly from cardiologists, nephrologists and consultant physicians.
Why Eplerenone is a High-Potential Molecule for Distributors
Heart failure and resistant hypertension are chronic conditions requiring lifelong therapy, so eplerenone generates continuous repeat prescriptions. Its key advantage — a much lower rate of the hormonal side effects that limit spironolactone — is steadily shifting cardiologists toward it, especially for younger and male patients. That switch trend, in a growing cardiac-disease market, makes it a rising molecule for distributors.
Why Choose Cafoli Lifecare
Cafoli Lifecare provides territory-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, complete promotional inputs and the backing of 1000+ franchise partners across India.
References
- MedlinePlus: Eplerenone
- PubChem: Eplerenone
Our formulations of Eplerenone find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: